LYRA241220P5000
- 0.00
- 0.000.00%
Lyra Therapeutics Newsroom
Lyra Therapeutics: Hold Rating Due to Uncertainty in ENLIGHTEN-2 Trial Outcomes
Express News | Lyra Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Sales Results
BTIG Maintains Lyra Therapeutics(LYRA.US) With Hold Rating
Lyra Therapeutics | 10-Q: Q3 2024 Earnings Report
Lyra Therapeutics | 8-K: Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | Lyra Therapeutics Q3 EPS USD -0.18
Press Release: Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Lyra Therapeutics 3Q Loss/Shr 18c >LYRA
Express News | Lyra Therapeutics Inc - Topline Results From Enlighten 2 Expected in Q2 2025
Express News | Lyra Therapeutics Fully Enrolls Pivotal Phase 3 Enlighten 2 Trial of Lyr-210 for the Treatment of Chronic Rhinosinusitis
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
Lyra Health Selected for BenefitsPRO's 2024 Luminaries Awards
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
Lyra Health and Hazelden Betty Ford Foundation Announce Comprehensive Care Program for Individuals and Families Struggling With Substance Use Disorder
Lyra Health Announces First and Only Nationwide Networks for Dialectical Behavioral Therapy and Alcohol and Substance Use Disorders
Lyra Mental Health Care Delivers Significant Net Health Care Savings
Lyra Therapeutics Insiders Still US$66k Away From Original Investment Value
Express News | Perceptive Advisors LLC Reports 19.5% Stake in Lyra Therapeutics as of Aug 14 Vs 24.3% as of Feb 14- SEC Filing
Lyra Therapeutics Still Sees Potential in Rhinosinusitis Asset Despite Setbacks